These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9790791)

  • 21. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
    Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
    Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
    Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
    Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
    Bowman A; Gabra H; Langdon SP; Lessells A; Stewart M; Young A; Smyth JF
    Clin Cancer Res; 2002 Jul; 8(7):2233-9. PubMed ID: 12114425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
    Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
    Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
    Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
    Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E-Cadherin complex protein expression and survival in ovarian carcinoma.
    Davidson B; Gotlieb WH; Ben-Baruch G; Nesland JM; Bryne M; Goldberg I; Kopolovic J; Berner A
    Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.